hTERT gene expression in umbilical cord stem cells prevents the functional decline of their extracellular vesicles that occurs with cellular aging, preserving their ability to modulate immune responses and support ovarian tissue. This addresses a critical barrier to the clinical scalability of cell-derived therapeutic vesicles by stabilizing their biological potency across extended culture periods.
Key Points
- hTERT blocks senescence markers and mitochondrial dysfunction in aging stem cells
- Preserved vesicles maintain immunomodulatory function through altered microRNA cargo
- Young-like vesicles restore ovarian protective effects in aged female mice
Longevity Analysis
Cellular senescence—the loss of proliferative capacity and altered secretory function—degrades the therapeutic potential of cell-derived therapies over time. This research demonstrates that telomerase reactivation can decouple the aging process from functional decline, maintaining the signaling capacity of extracellular vesicles that regulate immune tolerance and tissue regeneration. For applications targeting reproductive aging and systemic inflammation, this stabilization of vesicle function addresses a fundamental manufacturing constraint that has limited the clinical development of cell-derived therapeutics. The retention of young-like protein and microRNA profiles suggests that senescence-driven changes in cell communication can be mechanically reversed, with direct implications for regenerative medicine and longevity interventions that depend on sustained cellular secretory capacity.
Original published by Wiley Aging Cell, by Yating Chen, Wei Liu, Ying Tian, Xinyu Wang, Haonan Fan, Mingyu Yang, Feiyang Diao, Jing Li .